Does Humana Cover Weight Loss Treatment in Delaware? A 2026 Guide

Last updated: July 24, 2026

Quick Facts. Humana Weight Loss Coverage in Delaware (2026):

• Humana in Delaware: Medicare Advantage (MAPD) plans only. Humana does not offer individual/family ACA commercial plans in Delaware.
• PBM: Humana Pharmacy Solutions (HPS) administers Part D prescription benefits.
• Medicare GLP-1 Bridge (July 1, 2026): Eligible Humana MAPD members may access Wegovy, Zepbound, and Foundayo at $50/month through a CMS initiative. Outside the standard HPS Part D formulary.
• § 3343 Parity: Del. Code Ann. tit. 18, § 3343 does NOT govern weight loss treatment coverage. Weight loss is not a mental health or substance use disorder condition, and federal CMS regulations (42 CFR Part 422) preempt state insurance law for Medicare Advantage plans.
• Delaware EPCS: Phentermine and Qsymia (Schedule IV) require electronic prescribing under Delaware law. GLP-1 agonists, Contrave, and orlistat are non-scheduled. EPCS is entirely inapplicable.
• Key Contacts: Humana Member Services 1-800-448-6262 | HPS 1-800-379-0092 | Delaware Bureau of Insurance 1-302-674-7300

If you have a Humana Medicare Advantage plan in Delaware and are exploring options for weight loss medication, the landscape changed significantly on July 1, 2026. A new CMS-administered Medicare GLP-1 Bridge program may allow eligible Humana MAPD members to access FDA-approved GLP-1 weight loss medications. Including Wegovy, Zepbound, and Foundayo. At a fixed $50/month cost-share, regardless of whether these drugs appear on the standard HPS Part D formulary.

This guide breaks down how Humana’s coverage of weight loss treatment works in Delaware, what the Medicare GLP-1 Bridge means for you, what medications may be available and at what cost, and how telehealth providers like Klarity can support your care.

See if you may qualify for weight loss treatment through Klarity Health.
Check your eligibility →

Medicare GLP-1 Bridge: The Major 2026 Update for Humana MAPD Members

Before July 1, 2026, Medicare Part D plans. Including those administered by Humana Pharmacy Solutions. Historically excluded most weight loss drugs under the traditional Part D non-coverage rule for “weight loss agents.” This meant GLP-1 receptor agonists prescribed specifically for weight loss (such as Wegovy and Zepbound) were generally not covered by HPS Part D formularies, even as their use surged nationwide.

That changed with the Medicare GLP-1 Bridge, a CMS-administered program launched July 1, 2026. Under this initiative:

• Eligible Medicare Advantage (MAPD) members. Including Humana MAPD members in Delaware. May access Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (semaglutide) at a fixed $50 per month cost-share.
• Coverage is provided outside the standard HPS Part D formulary. It is a CMS-funded bridge program, not a formulary tier.
• Eligibility criteria are set by CMS and may include BMI thresholds, qualifying comorbidities (such as hypertension, type 2 diabetes, or cardiovascular disease), and prior authorization through the CMS pathway.
• The program applies to MAPD plans, not standalone Part D plans or commercial insurance.

For Humana MAPD members in Delaware, this is a meaningful shift. To confirm your eligibility and initiate the GLP-1 Bridge benefit, call Humana Member Services at 1-800-448-6262 or visit your plan’s online portal. Coverage is not automatic. A prescriber must initiate the process, and CMS eligibility criteria apply.

Important: Ozempic and Mounjaro are GLP-1/GIP agonists approved for type 2 diabetes management, not for chronic weight management under Medicare. These drugs are not part of the Medicare GLP-1 Bridge program. If a provider prescribes semaglutide or tirzepatide for weight loss, the GLP-1 Bridge-eligible brands are Wegovy, Zepbound, and Foundayo.

Humana in Delaware: Medicare Advantage Only

Humana operates in Delaware exclusively as a Medicare Advantage (MAPD) carrier. There are no Humana commercial individual or family health insurance plans available in Delaware. If you are under age 65 and enrolled in a Humana plan, you are either on a Medicare Advantage plan (if you qualify for Medicare due to disability) or a plan obtained through a prior employer group arrangement.

For most Delaware residents who are 65 or older, Humana’s weight loss coverage operates entirely under Medicare Advantage rules governed by CMS (42 CFR Part 422). This is a critical distinction:

• Delaware state insurance law. Including Del. Code Ann. tit. 18, § 3343 (mental health and substance use disorder parity). Does NOT govern Humana MAPD plans. Federal law preempts state regulation of Medicare Advantage benefit design.
• Weight loss treatment is not a mental health or substance use disorder (MH/SUD) condition, so § 3343’s parity requirements do not apply even to the extent state law might otherwise reach commercial plans.
• Coverage determinations are made under CMS regulations, Humana’s Plan Benefit Package (PBP) filed annually with CMS, and the HPS Part D formulary.

HPS Part D Weight Loss Formulary (2026)

Under the standard HPS Part D formulary, most dedicated weight loss medications are excluded from coverage due to the Medicare Part D weight loss drug exclusion. The Medicare GLP-1 Bridge creates an alternative pathway for GLP-1 agonists. The table below summarizes coverage status and Delaware EPCS requirements for common weight loss medications:

Delaware EPCS Requirements for Weight Loss Medications

Delaware has one of the broadest electronic prescribing for controlled substances (EPCS) requirements in the country, covering Schedule II through Schedule V substances. For weight loss medications, this has limited practical impact because most modern obesity pharmacotherapy uses non-scheduled drugs. However, two medications are Schedule IV and trigger the requirement:

For telehealth providers, the practical implication is that prescribing phentermine or Qsymia to a Delaware patient requires a prescriber with electronic prescribing capability for controlled substances. GLP-1 agonists. Which represent the most clinically significant weight loss medications available in 2026. Have no EPCS requirement in Delaware because they are not scheduled substances.

Why § 3343 Does Not Apply to Weight Loss Coverage Disputes with Humana

Delaware’s mental health parity law, Del. Code Ann. tit. 18, § 3343, requires health insurers to cover mental health and substance use disorder (MH/SUD) treatment on terms no more restrictive than those applied to comparable medical/surgical benefits. Weight loss treatment falls outside this parity framework for two independent reasons:

1. Scope: § 3343 governs MH/SUD conditions. Obesity and weight management are not classified as mental health or substance use disorders under Delaware parity law or federal MHPAEA. A coverage denial for weight loss medication cannot be challenged on § 3343 parity grounds.
2. Federal preemption: Even if weight loss treatment were within the MH/SUD scope, Delaware state insurance law does not govern Medicare Advantage plans. Humana MAPD plans are regulated exclusively by CMS under 42 CFR Part 422. State-level complaints to the Delaware Bureau of Insurance do not resolve Medicare Advantage coverage disputes.

If you have a coverage dispute with your Humana MAPD plan regarding weight loss treatment, the correct pathway is the federal Medicare appeal process, not a state parity complaint.

How to Request Coverage Under the Medicare GLP-1 Bridge

Accessing the $50/month GLP-1 Bridge benefit through your Humana MAPD plan requires working through your prescriber and Humana’s CMS-aligned process. The general pathway is:

1. Establish clinical eligibility: Your provider documents your BMI, qualifying comorbidities (e.g., cardiovascular disease, hypertension, type 2 diabetes, sleep apnea), and weight management history.
2. Select a GLP-1 Bridge-eligible medication: Wegovy, Zepbound, or Foundayo. Note that Ozempic and Mounjaro are not part of the Bridge program.
3. Prior authorization through CMS pathway: Your prescriber submits clinical documentation to Humana/HPS confirming CMS eligibility criteria are met.
4. Pharmacy fulfillment: Once authorized, the medication is dispensed through an HPS-preferred pharmacy at the $50/month cost-share established by CMS.
5. Ongoing monitoring: CMS may require periodic clinical check-ins or documentation of weight loss response to maintain coverage.

To initiate this process, contact Humana Member Services at 1-800-448-6262 or HPS at 1-800-379-0092 to confirm your plan’s current participation in the Medicare GLP-1 Bridge and to obtain current prior authorization forms.

Federal Appeal Process for Coverage Denials

If Humana denies coverage for a weight loss medication or GLP-1 Bridge access, you have the right to appeal through the federal Medicare appeals process. This is a five-step pathway:

1. Redetermination: Request a redetermination from Humana within 60 days of the denial notice.
2. Reconsideration: If Humana upholds the denial, request reconsideration by a Qualified Independent Contractor (QIC). Currently Maximus Federal Services (1-855-887-6668).
3. Administrative Law Judge (ALJ) hearing: If the amount in dispute meets the threshold (check the current year’s amount with CMS), you may request an ALJ hearing.
4. Medicare Appeals Council: You may appeal an ALJ decision to the Medicare Appeals Council.
5. Federal district court: As a final step, judicial review is available if the amount in dispute meets the federal court threshold.

Unlike commercial plan members who file parity complaints with the Delaware Bureau of Insurance, Humana MAPD members must use this federal Medicare appeal pathway. The Delaware Bureau of Insurance (1-302-674-7300) has limited jurisdiction over Medicare Advantage coverage decisions.

Dual-Eligible (Medicare + DelawareCare) Members

Some Humana MAPD members in Delaware are dual-eligible. Enrolled in both Medicare and Delaware’s Medicaid program (DelawareCare). For dual-eligible members, weight loss medication coverage may be available through both the Medicare GLP-1 Bridge and, in some circumstances, through DelawareCare’s drug benefit. Key points:

• DelawareCare (Delaware Medicaid) has separate formulary and prior authorization criteria from HPS Part D.
• For dual-eligible members enrolled in a Humana Dual Eligible Special Needs Plan (D-SNP), benefit coordination between Medicare and DelawareCare may affect cost-sharing for weight loss medications.
• Contact Delaware DHHS at 1-800-372-2022 or Delaware SHIP (State Health Insurance Assistance Program) at 1-800-336-9500 for guidance on coordinating benefits.
• Cost-sharing assistance through the Low Income Subsidy (LIS/Extra Help) program may reduce the $50/month GLP-1 Bridge cost-share for qualifying dual-eligible members.

How Humana Compares to Other Delaware Insurers for Weight Loss

Humana’s MAPD-only footprint and the Medicare GLP-1 Bridge create a different coverage story than commercial Delaware plans:

If you are shopping plans or comparing options, commercial members should verify Zepbound and Wegovy status with their PBM. Humana MAPD members should start with the Medicare GLP-1 Bridge pathway rather than assuming standard Part D exclusion still blocks access.

Weight Loss Treatment at Klarity Health

Klarity Health connects Delaware residents with licensed weight loss providers through a streamlined telehealth platform. With a network of 2,000+ licensed providers across the country. Including those licensed in Delaware. Klarity offers:

• Comprehensive weight loss consultations with board-certified providers
• Evaluation for GLP-1 medications and other FDA-approved obesity pharmacotherapy
• Electronic prescribing (EPCS-capable for Schedule IV medications like phentermine where clinically appropriate)
• Ongoing care management and medication monitoring
• Assistance understanding your Humana MAPD benefits and what may be covered under the Medicare GLP-1 Bridge

Coverage through your Humana plan varies by specific plan, formulary year, and CMS eligibility criteria. Klarity recommends verifying your current benefits with Humana before your appointment. Most patients know within minutes whether they may be a candidate for GLP-1 therapy.

Explore weight loss treatment options with a licensed Klarity provider.
See if you may qualify →

5-Step Checklist: Verify Your Humana Weight Loss Benefits in Delaware

1. Confirm you are on a Humana Medicare Advantage (MAPD) plan in Delaware (not a commercial plan from another carrier).
2. Call Humana at 1-800-448-6262 and ask whether your plan participates in the Medicare GLP-1 Bridge for Wegovy, Zepbound, and Foundayo.
3. Ask HPS (1-800-379-0092) for current prior authorization forms and CMS eligibility criteria (BMI, comorbidities).
4. If dual-eligible, contact DMAP at 1-800-372-2022 and ask about LIS/Extra Help impact on the $50/month cost-share.
5. If denied, start the federal Medicare appeal (Humana redetermination → Maximus IRE 1-855-887-6668). Do not rely on § 3343 or DE DOI external review for MAPD weight loss denials.

Frequently Asked Questions

Does Humana cover Wegovy in Delaware in 2026?

Humana MAPD members in Delaware may access Wegovy at $50/month through the Medicare GLP-1 Bridge, a CMS-administered program launched July 1, 2026. This is available outside the standard HPS Part D formulary. Prior authorization based on CMS eligibility criteria is required. Call Humana at 1-800-448-6262 to verify your specific plan’s participation.

Does Humana cover Zepbound for weight loss in Delaware?

Zepbound (tirzepatide) is one of the three GLP-1 medications included in the Medicare GLP-1 Bridge program. Eligible Humana MAPD members in Delaware may access it at $50/month through the CMS program. Prior authorization is required. Mounjaro (tirzepatide) is covered for type 2 diabetes under separate criteria and is not part of the Bridge program.

Can I file a parity complaint with the Delaware Bureau of Insurance against Humana?

No. The Delaware Bureau of Insurance does not have jurisdiction over Medicare Advantage plans. If Humana denies a weight loss coverage request, you must use the federal Medicare appeals process: redetermination through Humana → Maximus QIC (1-855-887-6668) → ALJ hearing. Additionally, § 3343 mental health parity law does not cover weight loss conditions.

Does phentermine require electronic prescribing in Delaware?

Yes. Phentermine is a Schedule IV controlled substance. Delaware’s EPCS law (Schedule II. V broad mandate) requires electronic prescribing for phentermine and Qsymia. Prescribers must use a certified EPCS-enabled system. GLP-1 medications (semaglutide, tirzepatide) are non-scheduled and have no EPCS requirement.

Does Humana offer commercial health plans in Delaware?

No. Humana exited the Delaware commercial individual and family health insurance market. In Delaware, Humana offers Medicare Advantage plans only. If you are under 65 (unless Medicare-eligible due to disability), you would need to obtain coverage through another insurer or the Delaware Health Insurance Marketplace.

What is the Medicare GLP-1 Bridge program?

The Medicare GLP-1 Bridge is a CMS-administered program launched July 1, 2026, that allows eligible Medicare Advantage members to access FDA-approved GLP-1 weight loss medications. Specifically Wegovy, Zepbound, and Foundayo. At a fixed $50/month cost-share. The program is funded through CMS and is distinct from the standard HPS Part D formulary. Eligibility criteria include BMI thresholds and qualifying comorbidities as defined by CMS.

Key Contacts

• Humana Member Services: 1-800-448-6262
• Humana Pharmacy Solutions (HPS): 1-800-379-0092
• Medicare GLP-1 Bridge / CMS: 1-800-633-4227 (Medicare helpline)
• Maximus IRE (Medicare appeals): 1-855-887-6668
• Delaware Bureau of Insurance: 1-302-674-7300 (commercial plans only; no jurisdiction over MAPD)
• Delaware DHHS (DelawareCare): 1-800-372-2022
• Delaware SHIP: 1-800-336-9500
• DOL EBSA (employer plan issues): 1-866-444-3272

Disclaimer: Coverage details, formulary tiers, and program eligibility may change at any time. The Medicare GLP-1 Bridge program criteria and cost-share amounts are established by CMS and are subject to annual revision. This article is for informational purposes only and does not constitute medical or legal advice. Always verify your specific plan’s current benefits by contacting Humana directly before scheduling an appointment or filling a prescription. Coverage varies by plan and individual eligibility.